Predicting the development of Cushing's syndrome in medullary thyroid cancer: Utility of proopiomelanocortin messenger ribonucleic acid in situ hybridization

Mae Sheikh-Ali, Murli Krishna, Ricardo Lloyd, Robert Christian Smallridge

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To determine the ability to predict the development of Cushing's syndrome (CS) by immunostaining prior to its clinical recognition. Design: In the current report, we demonstrated that a medullary thyroid carcinoma (MTC) patient had the ability to develop CS several years before its clinical recognition. Special stains on tumor tissue confirmed the presence of ectopic adrenocorticotropic hormone (ACTH) 3 years before his clinical presentation of CS. Subsequently, we identified eight MTC patients and reviewed their records to determine whether there was clinical or laboratory evidence of CS. Tissue blocks were obtained from the primary tumor and metastasic lesions for ACTH staining and for proopiomelanocortin messenger ribonucleic acid (POMC mRNA) in situ hybridization. Chromogranin A staining was also performed. Main outcome: ACTH staining did not detect ectopic ACTH. However, measuring ACTH precursor (POMC mRNA) by in situ hybridization confirmed the diagnosis, which preceded the patient's clinical presentation by 3 years. We also found that in a small series of eight MTC patients, most with metastatic disease, there was no histologic evidence of ACTH or POMC production. Conclusion: Our current report demonstrates that ACTH staining may not detect ACTH, but measuring POMC mRNA by in situ hybridization is very helpful in confirming the source of ectopic ACTH production.

Original languageEnglish (US)
Pages (from-to)631-634
Number of pages4
JournalThyroid
Volume17
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Pro-Opiomelanocortin
Cushing Syndrome
Adrenocorticotropic Hormone
In Situ Hybridization
RNA
Ectopic Hormones
Staining and Labeling
Medullary Thyroid cancer
Chromogranin A
Neoplasms
Coloring Agents

ASJC Scopus subject areas

  • Endocrinology

Cite this

Predicting the development of Cushing's syndrome in medullary thyroid cancer : Utility of proopiomelanocortin messenger ribonucleic acid in situ hybridization. / Sheikh-Ali, Mae; Krishna, Murli; Lloyd, Ricardo; Smallridge, Robert Christian.

In: Thyroid, Vol. 17, No. 7, 07.2007, p. 631-634.

Research output: Contribution to journalArticle

@article{9ec47e5dd2e14ed185779da3328cb0f2,
title = "Predicting the development of Cushing's syndrome in medullary thyroid cancer: Utility of proopiomelanocortin messenger ribonucleic acid in situ hybridization",
abstract = "Objective: To determine the ability to predict the development of Cushing's syndrome (CS) by immunostaining prior to its clinical recognition. Design: In the current report, we demonstrated that a medullary thyroid carcinoma (MTC) patient had the ability to develop CS several years before its clinical recognition. Special stains on tumor tissue confirmed the presence of ectopic adrenocorticotropic hormone (ACTH) 3 years before his clinical presentation of CS. Subsequently, we identified eight MTC patients and reviewed their records to determine whether there was clinical or laboratory evidence of CS. Tissue blocks were obtained from the primary tumor and metastasic lesions for ACTH staining and for proopiomelanocortin messenger ribonucleic acid (POMC mRNA) in situ hybridization. Chromogranin A staining was also performed. Main outcome: ACTH staining did not detect ectopic ACTH. However, measuring ACTH precursor (POMC mRNA) by in situ hybridization confirmed the diagnosis, which preceded the patient's clinical presentation by 3 years. We also found that in a small series of eight MTC patients, most with metastatic disease, there was no histologic evidence of ACTH or POMC production. Conclusion: Our current report demonstrates that ACTH staining may not detect ACTH, but measuring POMC mRNA by in situ hybridization is very helpful in confirming the source of ectopic ACTH production.",
author = "Mae Sheikh-Ali and Murli Krishna and Ricardo Lloyd and Smallridge, {Robert Christian}",
year = "2007",
month = "7",
doi = "10.1089/thy.2007.0062",
language = "English (US)",
volume = "17",
pages = "631--634",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Predicting the development of Cushing's syndrome in medullary thyroid cancer

T2 - Utility of proopiomelanocortin messenger ribonucleic acid in situ hybridization

AU - Sheikh-Ali, Mae

AU - Krishna, Murli

AU - Lloyd, Ricardo

AU - Smallridge, Robert Christian

PY - 2007/7

Y1 - 2007/7

N2 - Objective: To determine the ability to predict the development of Cushing's syndrome (CS) by immunostaining prior to its clinical recognition. Design: In the current report, we demonstrated that a medullary thyroid carcinoma (MTC) patient had the ability to develop CS several years before its clinical recognition. Special stains on tumor tissue confirmed the presence of ectopic adrenocorticotropic hormone (ACTH) 3 years before his clinical presentation of CS. Subsequently, we identified eight MTC patients and reviewed their records to determine whether there was clinical or laboratory evidence of CS. Tissue blocks were obtained from the primary tumor and metastasic lesions for ACTH staining and for proopiomelanocortin messenger ribonucleic acid (POMC mRNA) in situ hybridization. Chromogranin A staining was also performed. Main outcome: ACTH staining did not detect ectopic ACTH. However, measuring ACTH precursor (POMC mRNA) by in situ hybridization confirmed the diagnosis, which preceded the patient's clinical presentation by 3 years. We also found that in a small series of eight MTC patients, most with metastatic disease, there was no histologic evidence of ACTH or POMC production. Conclusion: Our current report demonstrates that ACTH staining may not detect ACTH, but measuring POMC mRNA by in situ hybridization is very helpful in confirming the source of ectopic ACTH production.

AB - Objective: To determine the ability to predict the development of Cushing's syndrome (CS) by immunostaining prior to its clinical recognition. Design: In the current report, we demonstrated that a medullary thyroid carcinoma (MTC) patient had the ability to develop CS several years before its clinical recognition. Special stains on tumor tissue confirmed the presence of ectopic adrenocorticotropic hormone (ACTH) 3 years before his clinical presentation of CS. Subsequently, we identified eight MTC patients and reviewed their records to determine whether there was clinical or laboratory evidence of CS. Tissue blocks were obtained from the primary tumor and metastasic lesions for ACTH staining and for proopiomelanocortin messenger ribonucleic acid (POMC mRNA) in situ hybridization. Chromogranin A staining was also performed. Main outcome: ACTH staining did not detect ectopic ACTH. However, measuring ACTH precursor (POMC mRNA) by in situ hybridization confirmed the diagnosis, which preceded the patient's clinical presentation by 3 years. We also found that in a small series of eight MTC patients, most with metastatic disease, there was no histologic evidence of ACTH or POMC production. Conclusion: Our current report demonstrates that ACTH staining may not detect ACTH, but measuring POMC mRNA by in situ hybridization is very helpful in confirming the source of ectopic ACTH production.

UR - http://www.scopus.com/inward/record.url?scp=34548153463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548153463&partnerID=8YFLogxK

U2 - 10.1089/thy.2007.0062

DO - 10.1089/thy.2007.0062

M3 - Article

C2 - 17696832

AN - SCOPUS:34548153463

VL - 17

SP - 631

EP - 634

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 7

ER -